<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444132</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-05-3621-SM-CTIL</org_study_id>
    <nct_id>NCT00444132</nct_id>
  </id_info>
  <brief_title>Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS</brief_title>
  <official_title>Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <brief_summary>
    <textblock>
      Laboratory clopidogrel resistance is associated with adverse atherothrombotic events in&#xD;
      patients with coronary artery disease. In the proposed study we wish to prospectively assess&#xD;
      the effect of reloading with 600 mg clopidogrel, and administer maintenance treatment with&#xD;
      clopidogrel 150 mg/day for one month in a group of acute myocardial infarction (AMI) patients&#xD;
      who demonstrate non-responsiveness to clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior studies have demonstrated significant variability in platelet response to clopidogrel&#xD;
      in patients with coronary artery disease (CAD). Up to 25% of patients have been shown to be&#xD;
      non-responders to a conventional dose of clopidogrel. This phenomenon has been associated&#xD;
      with higher incidence of recurrent cardiovascular (CVS) adverse events in patients with acute&#xD;
      coronary syndrome (ACS), and higher incidence of peri-procedural myocardial damage,&#xD;
      thrombotic complications, and ischemic events in patients undergoing elective percutaneous&#xD;
      coronary intervention (PCI). Both the ex-vivo anti-platelet effect and the clinical benefit&#xD;
      of clopidogrel are dose related. Moreover, in patients sustaining ACS while on maintenance&#xD;
      clopidogrel treatment, reloading with 600 mg clopidogrel, resulted in further reduction in&#xD;
      platelet aggregation, although the patients were not non-responders. Despite this, the effect&#xD;
      of dose escalation has never been examined in patients resistant to clopidogrel. In the&#xD;
      present study we wish to assess prospectively the effect of reloading with 600 mg&#xD;
      clopidogrel, and double dose maintenance treatment (150 mg/day) for one month in acute&#xD;
      myocardial infarction (AMI) patients who demonstrate non-respondese to clopidogrel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrent ACS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Clopidogrel Non-Responsiveness</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age equal or over 18 years&#xD;
&#xD;
          -  acute coronary syndrome&#xD;
&#xD;
          -  Clopidogrel non-responsive&#xD;
&#xD;
          -  signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  hypersensitivity to aspirin or clopidogrel&#xD;
&#xD;
          -  any contraindication to anti-thrombotic or anticoagulant therapy&#xD;
&#xD;
          -  active neoplastic disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shlomi Matetzky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Physician, ICCU, Sheba Medical Center.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICCU, Sheba Medical Center</name>
      <address>
        <city>Tel-hashomer, Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>March 6, 2007</study_first_submitted>
  <study_first_submitted_qc>March 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2007</study_first_posted>
  <last_update_submitted>September 19, 2007</last_update_submitted>
  <last_update_submitted_qc>September 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2007</last_update_posted>
  <keyword>clopidogrel</keyword>
  <keyword>platelets</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

